• Subscribe
  • Log In
  • Home
  • Daily Diary
  • Asset Class
    • U.S. Equity
    • Fixed Income
    • Global Equity
    • Commodities
    • Currencies
  • Sector
    • Basic Materials
    • Consumer Discretionary
    • Consumer Staples
    • Energy
    • Financial Services
    • Healthcare
    • Industrials
    • Real Estate
    • Technology
    • Telecom Services
    • Transportation
    • Utilities
  • Latest
    • Articles
    • Video
    • Columnist Conversations
    • Best Ideas
    • Stock of the Day
  • Street Notes
  • Authors
    • Doug Kass
    • Bruce Kamich
    • Jim Cramer
    • Jim "Rev Shark" DePorre
    • Helene Meisler
    • Jonathan Heller
    • - See All -
  • Options
  • RMPIA
  • Switch Product
    • Action Alerts PLUS
    • Quant Ratings
    • Real Money
    • Real Money Pro
    • Retirement
    • Stocks Under $10
    • TheStreet
    • Top Stocks
    • Trifecta Stocks
  1. Home
  2. / Investing
  3. / Stocks

Amgen Charts Indicate Shares Want to Work Their Way Higher Longer Term

Amgen's deal to buy Otezla from Celgene should not deter the drugmaker's stock from gaining ground over the long haul.
By BRUCE KAMICH
Aug 26, 2019 | 09:53 AM EDT
Stocks quotes in this article: AMGN, CELG, BMY

Amgen Inc. ( AMGN) is the Stock of the Day at Real Money here on Monday as it has agreed to acquire the global rights to Celgene Corp.'s ( CELG) psoriasis medication Otezla for $13.4 billion in cash. Celgene is selling Otezla so that regulators will allow its planned sale to Bristol-Myers Squibb Co. ( BMY)  to proceed. A lot of my neighbors in New Jersey are involved in the drug industry, so I will leave the fine details up to them and just concentrate on the charts and indicators of Amgen, which is a holding of Jim Cramer's Action Alerts PLUS charitable trust.
 
In this daily bar chart of AMGN, below, we can see the price action through Friday's close. Amgen was trading around $196 in pre-market activity on Monday but opened at more than $200. If the shares fall back to the $195 area here on Monday it could be a normal pullback after the price strength seen earlier this month, and the $195 area also can be viewed as a reversal from prior resistance in April to support today. Even with a dip prices would be above the rising 50-day moving average line and rising 200-day line. The volume of trading this month has been heavier than in July and the On-Balance-Volume (OBV) line made a new high for the move up. The Moving Average Convergence Divergence (MACD) oscillator has narrowed recently and could cross to the downside for a take profits sell signal.
 
 
 
 
In this weekly bar chart of AMGN, below, we can see the past three years. This chart shows an uptrend from late 2016 but with lots of pullbacks along the way. Prices are testing the 2018 highs and are above the rising 40-week moving average line. The weekly OBV line has broken out to a new high over the 2018 highs for this indicator. This is a very positive development. The weekly MACD oscillator is poised to cross the zero line and an outright go long signal.
 
 
 
 
In this weekly Point and Figure chart of AMGN, below, a potential longer-term price target of $231 is indicated.
 
 
 
Bottom line strategy: Traders, investors and analysts may or may not need a day or two to digest the latest corporate news. Longer term, I would look for prices to work higher. A trade at $211.69 would refresh the uptrend.
Get an email alert each time I write an article for Real Money. Click the "+Follow" next to my byline to this article.

Employees of TheStreet are prohibited from trading individual securities.

TAGS: Mergers and Acquisitions | Investing | Stocks | Technical Analysis | Biotechnology | Healthcare | Pharmaceuticals | Action Alerts PLUS | Real Money | Stock of the Day

More from Stocks

Emotions Run High as Indexes Slip

James "Rev Shark" DePorre
Jan 27, 2021 4:44 PM EST

I've raised a bit of cash, but it's still unclear what will emerge from here.

3 Important Questions the Fed Answered Wednesday

Tom Graff
Jan 27, 2021 4:30 PM EST

Powell was asked a number of questions about asset bubbles and financial stability risks during his press conference.

'Mortal Kombat' on the Market

Peter Tchir
Jan 27, 2021 3:54 PM EST

Let's pick apart the wild action in individual stocks -- especially GameStop -- and see what to expect going forward.

Butterflies Are Free: This GameStop Options Play Is Hardly Ever Seen

Timothy Collins
Jan 27, 2021 3:01 PM EST

I'll take a 66% risk-free rate of return in six months anytime.

Walgreens Boots Alliance Rallies Ahead of Earnings

Bruce Kamich
Jan 27, 2021 2:45 PM EST

Has WBA rallied too much?

Real Money's message boards are strictly for the open exchange of investment ideas among registered users. Any discussions or subjects off that topic or that do not promote this goal will be removed at the discretion of the site's moderators. Abusive, insensitive or threatening comments will not be tolerated and will be deleted. Thank you for your cooperation. If you have questions, please contact us here.

Email

CANCEL
SUBMIT

Email sent

Thank you, your email to has been sent successfully.

DONE

Oops!

We're sorry. There was a problem trying to send your email to .
Please contact customer support to let us know.

DONE

Please Join or Log In to Email Our Authors.

Email Real Money's Wall Street Pros for further analysis and insight

Already a Subscriber? Login

Columnist Conversation

  • 11:48 AM EST STEPHEN GUILFOYLE

    Cashing in Some More Chips at Stocks Under $10

    We're trimming a position for a big gain today.
  • 08:34 AM EST GARY BERMAN

    Wednesday Morning Fibocall for 1/27/2021

    The "correction" can be coming sooner than we thou...
  • 09:35 AM EST CHRIS VERSACE

    Another Big Winner for Stocks Under $10

    We're ringing the register Tuesday morning.
  • See More

COLUMNIST TWEETS

  • A Twitter List by realmoney
About Privacy Terms of Use

© 1996-2021 TheStreet, Inc., 225 Liberty Street, 27th Floor, New York, NY 10281

Need Help? Contact Customer Service

Except as otherwise indicated, quotes are delayed. Quotes delayed at least 20 minutes for all exchanges. Market Data & Company fundamental data provided by FactSet. Earnings and ratings provided by Zacks. Mutual fund data provided by Valueline. ETF data provided by Lipper. Powered and implemented by FactSet Digital Solutions Group.

TheStreet Ratings updates stock ratings daily. However, if no rating change occurs, the data on this page does not update. The data does update after 90 days if no rating change occurs within that time period.

FactSet calculates the Market Cap for the basic symbol to include common shares only. Year-to-date mutual fund returns are calculated on a monthly basis by Value Line and posted mid-month.

Compare Brokers

Please Join or Log In to manage and receive alerts.

Follow Real Money's Wall Street Pros to receive real-time investing alerts

Already a Subscriber? Login